Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - leuprorelin acetate -

Australia - English - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - ulipristal acetate -

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - leuprorelin acetate 3.75mg (powder for injection compartment) - injection (depot) - 3.75 mg - active: leuprorelin acetate 3.75mg (powder for injection compartment) excipient: acetic acid carmellose sodium gelatin plga (copoly (dl-lactic acid/glycolic acid) 75:25mol%) powder for injection compartment mannitol polysorbate 80 water for injection - lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - leuprorelin acetate 11.25mg (powder for injection compartment) - injection (depot) - 11.25 mg - active: leuprorelin acetate 11.25mg (powder for injection compartment) excipient: carmellose sodium glacial acetic acid polylactic acid (pla) powder for injection compartment mannitol polysorbate 80 water for injection - lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - leuprorelin acetate 30mg (powder for injection compartment) - injection (depot) - 30 mg - active: leuprorelin acetate 30mg (powder for injection compartment) excipient: carmellose sodium glacial acetic acid lactic acid mannitol polysorbate 80 water for injection - lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression

Canada - English - Health Canada

verity pharmaceuticals inc. - leuprolide acetate - powder for suspension, sustained-release - 22.5mg - leuprolide acetate 22.5mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

tap pharmaceutical products inc. - leuprolide acetate (unii: 37jns02e7v) (leuprolide - unii:efy6w0m8tg) - kit - 5 mg in 1 ml - lupron injection (leuprolide acetate) is indicated in the palliative treatment of advanced prostatic cancer. - lupron injection is contraindicated in patients known to be hypersensitive to gnrh, gnrh agonist analogs or any of the excipients in lupron injection: reports of anaphylactic reactions to gnrh agonist analogs have been reported in the medical literature.1,2 - lupron is contraindicated in women who are or may become pregnant while receiving the drug. lupron may cause fetal harm when administered to a pregnant woman. therefore, the possibility exists that spontaneous abortion may occur if the drug is administered during pregnancy. if this drug is administered during pregnancy or if the patient becomes pregnant while taking any formulation of lupron, the patient should be apprised of the potential hazard to the fetus. lupron® injection (leuprolide acetate) rx only lupron injection is indicated in the treatment of children with central precocious puberty. children should be selected using the follow

Malta - English - Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - leuprorelin acetate - implant - leuprorelin acetate 5 mg - endocrine therapy